摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(4-fluorophenyl)oxy]pyridine-4-carbonitrile | 869299-30-9

中文名称
——
中文别名
——
英文名称
2-[(4-fluorophenyl)oxy]pyridine-4-carbonitrile
英文别名
2-(4-fluorophenoxy)isonicotinonitrile;2-(4-Fluorophenoxy)pyridine-4-carbonitrile
2-[(4-fluorophenyl)oxy]pyridine-4-carbonitrile化学式
CAS
869299-30-9
化学式
C12H7FN2O
mdl
MFCD09934070
分子量
214.199
InChiKey
MEZPLJLLXGQTME-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    317.9±37.0 °C(Predicted)
  • 密度:
    1.30±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    45.9
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2-[(4-fluorophenyl)oxy]pyridine-4-carbonitrile 在 sodium hydroxide 、 盐酸 作用下, 以 乙醇 为溶剂, 反应 16.0h, 生成 2-(4-fluorophenoxy)isonicotinic acid
    参考文献:
    名称:
    [EN] PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR
    [FR] PIPÉRIDINE-AMIDES EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA GHRÉLINE
    摘要:
    化合物的结构式(I)或其药学上可接受的盐,可用于治疗糖尿病和肥胖。
    公开号:
    WO2011117254A1
  • 作为产物:
    描述:
    2-氯-4-氰基吡啶4-氟苯酚 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 0.17h, 以81%的产率得到2-[(4-fluorophenyl)oxy]pyridine-4-carbonitrile
    参考文献:
    名称:
    SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS
    摘要:
    本发明提供了一种新型酰胺衍生物,具有基质金属蛋白酶抑制活性,并且作为药用剂是有用的,该化合物由以下式(I)表示,其中环A是一个可选择取代的含氮杂环,环B是一个可选择取代的单环同核环或可选择取代的单环杂环,Z是N或NR1(R1是氢原子或可选择取代的碳氢基团),是一个单键或双键,R2是氢原子或可选择取代的碳氢基团,X是一个具有1到6个原子的可选择取代的间隔物,环C是(1)一个可选择取代的同核环或(2)一个除了由(II)表示的环之外的可选择取代的杂环(X′是S、O、SO或CH2),并且环B和环C中至少有一个有取代基,但不包括N-{(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺,或其盐。
    公开号:
    US20150329556A1
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR<br/>[FR] COMPOSÉ AMIDE HETEROCYCLIQUE ET UTILISATION DE CELUI-CI EN TANT QU'INHIBITEUR MMP-13
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2005105760A1
    公开(公告)日:2005-11-10
    The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), - - - is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionnally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X’ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.
    本发明提供了一种新型酰胺衍生物,具有基质蛋白酶抑制活性,并且作为药用剂是有用的,该化合物由以下式(I)表示,其中环A是一个可选择取代的含氮杂环,环B是一个可选择取代的单环同核环或可选择取代的单环杂环,Z是N或NR1(R1是氢原子或可选择取代的碳氢基团),- - - 是一个单键或双键,R2是氢原子或可选择取代的碳氢基团,X是具有1到6个原子的可选择取代的间隔物,环C是(1)一个可选择取代的同核环或(2)除了由(II)表示的环之外的可选择取代的杂环(X'是S、O、SO或CH2),并且环B和环C中至少有一个具有取代基,但不包括N-(1S,2R)-1-(3,5-二苄基)-3-[(3-乙基苄基)基]-2-羟基丙基}-5,6-二甲基-4-氧代-1,4-二氢噻吩[2,3-d]嘧啶-2-羧酰胺或其盐。
  • Antiviral activity evaluation and action mechanism of chalcone derivatives containing phenoxypyridine
    作者:Piao Mao、Li Xing、Bangcan He、Tianyu Deng、Yishan Qin、Yuzhi Hu、Youshan An、Wei Xue
    DOI:10.1007/s11030-024-10843-7
    日期:2025.2
    In this paper, a series of phenoxypyridine-containing chalcone derivatives (L1–L28) were designed and synthesized, characterized on NMR and HRMS. Ningnanmycin (NNM) was used as a control agent. The results of the antiviral activity testing showed that the curative activity EC50 values of L1 and L4 against TMV were 140.5 and 90.7 μg/mL, respectively, which were superior to that of NNM (148.3 μg/mL)
    本文设计并合成了一系列含苯氧基吡啶查尔酮生物( L1 – L28 ),并通过NMR和HRMS进行了表征。宁南霉素(NNM)用作对照剂。抗病毒活性测试结果显示, L1和L4对TMV的疗效EC 50值分别为140.5和90.7 μg/mL,优于NNM(148.3 μg/mL)。 L1 、 L4和L15的抗TMV保护活性的EC 50值分别为154.1、102.6和140.0μg/mL,优于NNM(188.2μg/mL)。初步探讨了L4和NNM与烟草花叶病毒衣壳蛋白(TMV-CP)的作用机制。微尺度热泳(MST)实验结果表明, L4对TMV-CP具有很强的结合亲和力,解离常数Kd值为0.00149 µM,优于NNM(2.73016 µM)。分子对接实验结果表明, L4与TMV-CP的氨基酸残基形成的氢键比NNM更短,形成的氨基酸残基比NNM更多,这表明L4与TMV-CP的结合更紧密。本研究表明
  • HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1740551B1
    公开(公告)日:2012-09-12
  • Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio)
    申请人:Terauchi Jun
    公开号:US20080027050A1
    公开(公告)日:2008-01-31
    The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.
  • US9212149B2
    申请人:——
    公开号:US9212149B2
    公开(公告)日:2015-12-15
查看更多